These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 31921107)
1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A Front Immunol; 2019; 10():2802. PubMed ID: 31921107 [TBL] [Abstract][Full Text] [Related]
2. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Zheng T; Pang Z; Zhao Z Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073 [TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559 [TBL] [Abstract][Full Text] [Related]
4. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy. Zhao Y; Schaafsma E; Cheng C Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484 [TBL] [Abstract][Full Text] [Related]
5. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276 [TBL] [Abstract][Full Text] [Related]
6. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363 [TBL] [Abstract][Full Text] [Related]
7. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360 [TBL] [Abstract][Full Text] [Related]
9. Complete Metabolic Response on Interim Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466 [TBL] [Abstract][Full Text] [Related]
10. Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation. Vishnubalaji R; Abdel-Razeq H; Gehani S; Albagha OME; Alajez NM Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142814 [TBL] [Abstract][Full Text] [Related]
11. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131 [TBL] [Abstract][Full Text] [Related]
12. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068 [TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908 [TBL] [Abstract][Full Text] [Related]
15. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781 [TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586 [TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Orozco JIJ; Grumley JG; Matsuba C; Manughian-Peter AO; Chang SC; Chang G; Gago FE; Salomon MP; Marzese DM Ann Surg Oncol; 2019 Oct; 26(10):3185-3193. PubMed ID: 31342395 [TBL] [Abstract][Full Text] [Related]
18. A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Wang Q; Li C; Tang P; Ji R; Chen S; Wen J Cell Physiol Biochem; 2018; 48(6):2539-2548. PubMed ID: 30121642 [TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Neoadjuvant Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]